PF-Atlas › Clinical Trials › NCT03955146
Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis
Pamrevlumab · Phase 3
Registry ID
NCT03955146
Phase
Phase 3
Status
Terminated
Drug / intervention
Pamrevlumab
Sponsor
Kyntra Bio
Start
2019-06-18
Enrollment
393
Locations
125
About this trial
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with IPF.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT03955146 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.